Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 23;11(5):334.
doi: 10.3390/jpm11050334.

Targeted Therapies for Multiple Myeloma

Christopher Chang-Yew Leow  1 , Michael Sze Yuan Low  1
Affiliations
Review

Targeted Therapies for Multiple Myeloma

Christopher Chang-Yew Leow et al. J Pers Med. .

Abstract

Multiple myeloma continues to be a challenging disorder to treat despite improved therapies and the widespread use of proteasome inhibitors and immunomodulatory drugs. Although patient outcomes have improved, the disease continues to invariably relapse, and in the majority of cases, a cure remains elusive. In the last decade, there has been an explosion of novel drugs targeting cellular proteins essential for malignant plasma cell proliferation and survival. In this review, we focus on novel druggable targets leading to the development of monoclonal antibodies and cellular therapies against surface antigens (CD38, CD47, CD138, BCMA, SLAMF7, GPRC5D, FcRH5), inhibitors of epigenetic regulators such as histone deacetylase (HDAC), and agents targeting anti-apoptotic (BCL-2), ribosomal (eEF1A2) and nuclear export (XPO1) proteins.

Keywords: monoclonal antibody; multiple myeloma; therapeutic targets.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Therapeutic modalities in multiple myeloma.
See this image and copyright information in PMC

References

    1. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., THiele J., Arber D.A., Hasserjian R.P., Le Beau M.M., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. International Agency for Research on Cancer (IARC); Lyon, France: 2017.
    1. Hallek M., Bergsagel P.L., Anderson K.C. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood. 1998;91:3–21. doi: 10.1182/blood.V91.1.3. - DOI - PMC - PubMed
    1. Agarwal A., Ghobrial I.M. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: A review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin. Cancer Res. 2013;19:985–994. doi: 10.1158/1078-0432.CCR-12-2922. - DOI - PMC - PubMed
    1. Fonseca R., Bailey R.J., Ahmann G.J., Rajkumar S.V., Hoyer J.D., Lust J.A., Kyle R.A., Gertz M.A., Greipp P.R., Dewald G.W. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100:1417–1424. doi: 10.1182/blood.V100.4.1417.h81602001417_1417_1424. - DOI - PubMed
    1. Sawyer J.R. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 2011;204:3–12. doi: 10.1016/j.cancergencyto.2010.11.002. - DOI - PubMed